Panic disorder: A theoretical synthesis of medical and psychological approaches

Journal of Psychosomatic Research

Volumn 44, Issue 1, 1998, Pages 121-132

  Middleton, H C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cognitive psychology; Cognitive therapy; Neurobiology; Panic disorder; Pharmacotherapy

Indexed keywords

AGORAPHOBIA; AROUSAL; FEAR; HUMAN; MEDICAL PSYCHOLOGY; NORADRENERGIC SYSTEM; PANIC; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0031975872     PISSN: 00223999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3999(97)00208-0     Document Type: Article

References (97)

1. 1. World Health Organization. The ICD-10 Classification of mental and behavioural disorders. Geneva: World Health Organization 1992.
2. 2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: APA 1994.
3. 3. Siegel L, Jones WC, Wilson JO. Economic and life consequences experienced by a group of individuals with panic disorder. Anxiety Disord 1990;4:201-211.
4. 4. Klein DF, Ross DC, Cohen P. Panic and avoidance in agoraphobia: application of path analysis to treatment studies. Arch Gen Psychiatry 1987;44:377-385.
5. 5. Goisman RM, Warshaw MG, Stekete GS, Fierman EJ, Rogers MP, Goldenberg I, Weinshenker NJ, Vasile RG, Keller MB. DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis. Psychiatry 1995;152:1438-1443.
6. 6. Wittchen HU, Essau CA. Epidemiology of panic disorder: progress and unresolved issues. J Psychiatric Res 1993;27(Suppl 1):47-68.
7. 7. Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman G. Quality of life in panic disorder. Arch Gen Psychiatry 1989;46:984-992.
8. 8. Klerman GL, Weissman MM, Ouelette R, Johnson J, Greenwald S. Panic attacks in the community. Social morbidity and health care utilization. JAMA 1991;265:742-746.
9. 9. Beck AT, Sokol L, Clark DA, Berchick R, Wright F. A crossover study of focused cognitive therapy for panic disorder. Am J Psychiatry 1992;149:778-783.
10. 10. Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50.
11. 11. Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 1994;164:759-769.
12. 12. O'Rourke D, Fahy TJ, Brophy J, Prescott P. The Galway study of panic disorder. III. Outcome at 5 to 6 years. Br J Psychiatry 1996;168:462-469.
13. 13. Pollack MH, Otto MW, Rosenbaum JF, Sachs GS, O'Neil C, Asher R, Meltzer-Brody S, Longitudinal course of panic disorder: findings from the Massachusetts General Hospital naturalistic study. J Clin Psychiatry 1990;51(suppl A) 12-16.
14. 14. Wood P. Diseases of the heart and circulation, 3rd ed. Philadelphia: Lippincott 1968:17.
15. 15. Liberthson R, Sheehan DV, King ME, Weyman AE. The prevalence of mitral valve prolapse in patients with panic disorders. Am J Psychiatry 1986;143:511-515.
16. 16. Pitts FN, McClure JN. Lactate metabolism in anxiety neurosis. N Eng J Med 1967;25:1329-1336.
17. 17. Lum LC. The syndrome of chronic habitual hyperventilation. In: Hill OW, ed. Modern trends in psychosomatic medicine. London: Butterworth 1976.
18. 18. Papp LA, Martinez JM, Klein DF, Coplan JD, Gorman JM. Rebreathing tests in panic disorder. Biol Psychiatry 1995;38:240-245.
19. 19. Klein DF, Fink M. Psychiatric reaction patterns to imipramine Am J Psychiatry 1962;119:432-438.
20. 20. Mavissakalian M, Michelson L, Dealy RS. Pharmacological treatment of agorpahobia: imipramine versus imipramine with programmed practice. Br J Psychiatry 1983;143:348-355.
21. 21. Johnston DG, Troyer IE, Whittsett SF. Clomipramine treatment of agoraphobic women. Arch Gen Psychiatry 1988;45:805-808.
22. 22. Lydiard RB, Ballenger JC. Antidepressants in panic disorder and agoraphobia. J Affect Disord 1987;13:153-168.
23. 23. Hoehn-Saric R, McLeod D, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321-326.
24. 24. Silberman EK. Pharmacotherapy of anxiety disorders. In: Wolman B, Stricker G, eds. Anxiety and related disorders. New York: Wiley Interscience 1994:318-339.
25. 25. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990;47:889-907.
26. 26. Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and medication outcome after short-term alprazolam and behavioural group treatment in panic disorder: 2.5 year naturalistic follow-up study. Arch Gen Psychiatry 1989;46:993-999.
27. 27. Lucki I, Rickels K. The effect of anziolytic drugs on memory in anzious subjects. In: Hindmarch I, Otto H, eds. Benzodiazepine receptor ligands, memory and information processing, Berlin: Springer 1988:128-139.
28. 28. Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S, Wickwire K. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993;162:776-787.
29. 29. Ballenger JC, Peknold J, Rickels K, Sellers EM, Schatzberg AF, Shader RI. Medication discontinuation in panic disorder. J Clin Psychiatry 1993;54(suppl 10):15-21.
30. 30. Mavissakalian M. Combined behavioural therapy and pharmacotherapy of agoraphobia. J Psychiatry Res 1993;27(suppl 1):179-191.
31. 31. Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1986;43:1024-1054.
32. 32. Charney DS, Bremner JD, Redmond DE. Noradrenergic neural substrates for anxiety and fear. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press 1995:387-395.
33. 33. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991;30:1139-1166.
34. 34. Targum SD, Marshall. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989;28:295-306.
35. 35. Graeff FG, Guinares FS, De Andrade TGCS, Deakin JFW. Role of 5-HT in stress, anxiety and depression. Pharmacol Biochem Behav 1996;54:129-141.
36. 36. Gelder MG, Marks IM. Severe agoraphobia: a controlled prospective trial of behaviour therapy. Br J Psychiatry 1966;112:309-319.
37. 37. Mowrer OH. A stimulus-response analysis of anxiety and its role as a reinforcing agent. J Abnorm Psychol 1939;46:553-565.
38. 38. Meyer V. The treatment of two phobic patients on the basis of learning principles. J Abnorm Soc Psychol 1957;55:261-266.
39. 39. Wolpe J. Psychotherapy by reciprocal inhibition. Stanford, California: Stanford University Press Stanford 1985.
40. 40. Marks IM. Phobic disorders four years after treatment: a prospective follow-up. Br J Psychiatry 1971;118:683-687.
41. 41. Clark DM. A cognitive approach to panic. Behav Res Ther 1989;24:461-470.
42. 42. Brewin CR. Cognitive foundations of clinical psychology. London: Lawrence Erlbaum 1988.
43. 43. Rapee RM. Information-processing views of panic disorder. In: Rapee RM, ed. Current controversies in the anxiety disorders. New York: Guildford Press 1996:77-93.
44. 44. Beck AT, Clark DA. An information processing model of anxiety: automatic and strategic processes. Behav Res Ther 1997;35:49-58.
45. 45. Mathews A, MacLeod C. Selective processing of threat cues in anxiety states. Behav Res Ther 1985;23:563-569.
46. 46. Mathews A, MacLeod C. Discrimination of threat cues without awareness in anxiety states. J Abnorm Psychol 1986;95:131-138.
47. 47. MacLeod C, Mathews A, Tata P. Attentional bias in emotional disorders. J Abnorm Psychol 1986;95:15-20.
48. 48. Mathews A, May J, Mogg K, Eysenck MW. Attentional bias in anxiety: selective search or defective filtering? J Abnorm Psychol 1990;99:166-173.
49. 49. Mogg K, Mathews A, Eysenck M. Attentional bias to threat in clinical anxiety states. Cognition Emotion 1992;6:149-159.
50. 50. Asmundson GJG, Sandler LS, Wilson KG, Walker JR. Selective attention toward physical threat in patients with panic disorder. Journal of Anxiety Disorders 1992;6:295-303.
51. 51. McNally RJ, Amir N, Louro CE, Lukach BM, Riemann BC, Calamari JE. Cognitive processing of ideographic emotional information in panic disorder. Behav Res Ther 1994;32:119-122.
52. 52. Bower GH. Mood and memory. Am Psychol 1981;36:129-148.
53. 53. Williams JMG, Watts FN, MacLeod C, Mathews A. Cognitive psychology and emotional disorders. Wiley, Chichester 1988.
54. 54. MacLeod C, Mathews A. Biased cognitive operations in anxiety: accessibility of information or assignment of processing priorities? Behav Res Ther 1991;29:599-610.
55. 55. Oatley K, Johnson-Laird PN. Towards a cognitive theory of emotions. Cogn Emotion 1987;1:29-50.
56. 56. Rachman S. The conditioning theory of fear-acquisition: a critical examination. Behav Res Ther 1977;15:375-381.
57. 57. Marchione KE, Michelson L, Greenwald M, Dancu C. Cognitive behavioural treatment of agoraphobia. Behav Res Ther 1987;25:319-328.
58. 58. Schachter S, Singer J. Cognitive social and physiological determinants of emotional state. Psychol Rev 1962;69:379-397.
59. 59. Beck AT. Cognitive therapy and the emotional disorders. New York: International Universities Press 1976.
60. 60. Chambless DL, Caputo GC, Bright P, Gallagher R. Assessment of fear of fear in agoraphobics: the Bodily Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Consult Clin Psychol 1984;52:1090-1097.
61. 61. Warren R, Zgourides G, Englert M. relationships between catastrophic cognitions and body sensations in anxiety disordered, mixed diagnosis and normal subjects. Behav Res Ther 1990;28:355-357.
62. 62. Ehlers A. Cognitive factors in panic attacks: symptom probability and sensitivity. J Cognit Psychother 1991;5:157-173.
63. 63. Clark DM, Salkovskis PM, Gelder M, Koehler C, Martin M, Anastasiades P, Hackmann A, Middleton H, Jeavons A. Tests of a cognitive theory of panic. In: Hand I, Wittchen HU, eds. Panic and phobias 2. Berlin: Springer 1988:149-158.
64. 64. Clark DM. Cognitive mediation of panic attacks induced by biological challenge tests. Adv Behav Res Ther 1993;15:75-84.
65. 65. Clark DM, Ehlers A. Empirical status of the cognitive theory and treatment of panic disorder. Appl Prevent Psychol 1993;2:151-159.
66. 66. Clark DM, Salkovskis PM, Chalkley AJ. Respiratory control as a treatment for panic attacks. J Behav Ther Exp Psychiatry 1985;16:23-20.
67. 2. Br J Psychiatry 1989;148:526-532.
68. 68. Barlow DH, Craske M, Cerny J, Klosko J. Behavioural treatment of panic disorder. Behav Ther 1989;20:261-268.
69. 69. Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison of alprazolam, and behaviour therapy in the treatment of panic disorder. J Consult Clin Psychol 1990;58:77-84.
70. 70. Sokol L, Beck AT, Greenberg RL, Wright FD, Berchick RJ. Cognitive therapy of panic disorder: a non-pharmacological alternative. J Nerv Mental Disord 1989; 177:711-716.
71. 71. Salkovskis PM, Clark DM, Gelder MG. Cognition-behaviour links in the persistence of panic. Behav Res Ther 1996;34:453-458.
72. 72. Middleton HC. Non-random associations between fears, beliefs and behaviours amongst panic patients. Anxiety 1996;2:265-278.
73. 73. Broadbent DE. Perception and communication. London: Pergamon 1958.
74. 74. Pribram KH, McGuinness D. Arousal, activation and effort in the control of attention. Psychol Rev 1975;82:116-149.
75. 75. Pribram KH, McGuiness D. Attention and para-attentional processing. Event related potentials as tests of a model. Ann NY Acad Sci 1992;658:65-92.
76. 76. Schneider W, Shiffrin RM. Controlled and automatic human information processing. I: Detection, search and attention. Psychol Rev 1997;84:1-66.
77. 77. Shiffrin RM, Schneider W. Controlled and automatic human information processing. II: Automatic attending and a general theory. Psychol Rev 1977;84:127-190.
78. 78. Hasher L, Zacks RT. Automatic and effortful processes in memory. J Exp Psychol [Gen] 1979;108:356-388.
79. 79. Norman DA, Shallice T. Attention to action: willed and automatic control of behaviour. Technical report no. 99. Center for Human Information Processing 1980 (Reprinted in revised form in Davidson RJ, Schwartz SE, Shapiro D, (eds.) Consciousness and self-regulation (Vol 4). New York: Plenum Press 1986).
80. 80. Marsden CA. The neuropharmacology of serotonin in the central nervous system. In: Feighner JP, Boyer WF, eds. Selective serotonin re-uptake inhibitors. Chichester: Wiley 1996:1-33.
81. 81. Molliver MR. Serotonergic neuronal systems: what their anatomic organisation tells us about function. J of Clin Psychopharmacol 1987;7(suppl 6):3S-23S.
82. 82. Chopin P, Briley M. Animal models of anxiety: the effects of compounds that modify 5-HT neurotransmission. Trends Pharmacol Sci 1987;8:383-388.
83. 1 receptor antagonists administered into the peraqueductal grey. Psychopharmacology 1992;108:110-114.
84. 84. Linnoila M, Virkunnen M. Aggression, suicidality and serotonin. J Clin Psychiatry 1992;53(suppl 10):46-51.
85. 85. Carli M, Robbins TW, Evenden JL, Everitt BJ. Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction time task: implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 1983;9:361-380.
86. 86. Everitt BJ, Robbins TW, Gaskin M, Fray PJ. The effects of lesions to ascending noradrenergic neurons on discrimination learning and performance in rats. Neuroscience 1983;10:397-410.
87. 87. Selden NR, Cole BJ, Everitt BJ, Robbins TW. Damage to coeruleo-cortical projections impairs locally cued but enhances spatially cued water maze acquisition. Behav Brain Res 1990;39:29-51.
88. 88. Selden NR, Robbins TW, Everitt BJ. Enhanced behavioural conditioning to context and impaired behavioural and neuroendocrine responses to conditioned stimuli following coeruleo-cortical noradrenergic lesions; support for an attentional hypothesis of central noradrenergic function. J Neurosci 1990;10:531-539.
89. 89. Arnsten AFT, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side-effects. J Neurosci 1988;8:4287-4298.
90. 90. Mair RG, McEntee WJ. Korsakoff s psychosis; noradrenergic systems and cognitive impairment. Behav Brain Res 1983;9:1-32.
91. 91. Cole BJ, Robbins TW. Forebrain norepinephrine: role in controlled information processing in the rat. Neuropsychopharmacology 1992;7:129-142.
92. 92. Wesnes K, Warburton DM. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 1984;82:147-150.
93. 93. Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing and short term memory in patients with dementia of the Alzheimer type. Br Psychiatry 1989;154:797-800.
94. 94. Coull JT, Middleton HC, Robbins TW, Sahakian BJ. Clondine and diazepam have differential effects on tests of attention and learning. Psychopharmacology 1995;120:322-332.
95. 95. Coull JT, Frith CD, Grasby P. A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. J Psycnopharmacol 1995;9(suppl):A16.
96. 96. Aston-Jones G, Rajkowski J, Kubiak P, Alexinsky T. Locus coeruleus neurons are selectively activated by attended cues in a vigilance task. J of Neurosci 1994;14:4467-4480.
97. 97. Salkovskis PM, Clark DM. Cognitive therapy for panic disorder. J Cognit Psychother 1991;5:215-226.